An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will host a conference call on May 2, 2024, to discuss its first quarter 2024 financial results and corporate update. The call will focus on the development and commercialization of novel products for rare genetic diseases.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ospiterà una conferenza telefonica il 2 maggio 2024 per discutere i risultati finanziari del primo trimestre del 2024 e gli aggiornamenti aziendali. La chiamata sarà concentrata sullo sviluppo e la commercializzazione di prodotti innovativi per malattie genetiche rare.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) organizará una conferencia telefónica el 2 de mayo de 2024 para discutir los resultados financieros del primer trimestre de 2024 y la actualización corporativa. La llamada se centrará en el desarrollo y comercialización de productos novedosos para enfermedades genéticas raras.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)는 2024년 5월 2일에 2024년 1분기 재무 결과와 회사 업데이트에 대해 논의하기 위한 전화 회의를 주최할 예정입니다. 이 통화는 희귀 유전 질환을 위한 새로운 제품의 개발 및 상용화에 중점을 둘 것입니다.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) organisera une conférence téléphonique le 2 mai 2024 pour discuter des résultats financiers du premier trimestre de 2024 et des mises à jour de l'entreprise. L'appel se concentrera sur le développement et la commercialisation de produits novateurs pour les maladies génétiques rares.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) wird am 2. Mai 2024 einen Telefonkonferenz abhalten, um über die Finanzergebnisse des ersten Quartals 2024 und Unternehmensneuigkeiten zu sprechen. Der Anruf wird sich auf die Entwicklung und Vermarktung von neuen Produkten für seltene genetische Krankheiten konzentrieren.
Positive
None.
Negative
None.
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call, please register by clicking on the following link (registration link) and you will be provided with dial-in details. The replay of the call will be available for 3 months.
About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors Joshua Higa (415) 475-6370
Media Carolyn Wang (415) 225-5050
FAQ
When will Ultragenyx host a conference call for its first quarter 2024 financial results and corporate update?
Ultragenyx will host a conference call on May 2, 2024, at 5:00 p.m. ET.
What is the focus of Ultragenyx's conference call?
The conference call will discuss the development and commercialization of novel products for serious rare and ultrarare genetic diseases.
Where can the webcast of the conference call be accessed?
The live and replayed webcast of the call will be available through Ultragenyx's website at https://ir.ultragenyx.com/events-presentations.
How long will the replay of the conference call be available?
The replay of the call will be available for 3 months.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
